US2022202701A1PendingUtilityA1
Compositions and methods to promote wound healing
Est. expiryMar 11, 2035(~8.6 yrs left)· nominal 20-yr term from priority
Inventors:Fu-Shin X. Yu
C07K 14/545A61L 2300/432A61K 9/0019A61P 27/02A61L 2300/436A61K 38/1858A61K 47/38A61K 47/02A61L 15/28A61P 17/02A61L 2300/426A61L 15/60A61L 2300/414A61L 26/008A61L 15/18A61L 2430/32A61L 15/44A61K 9/06A61K 38/1793A61P 25/00A61L 2430/34A61K 9/0014A61L 26/0066
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure describes compositions and methods to promote wound healing. The compositions and methods include an interleukin-1 beta (IL-1β) receptor antagonist (IL-1Ra), such as anakinra. The IL-1Ra can be administered topically to a chronic wound including a diabetic ulcer.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A topical composition comprising a therapeutic agent consisting of:
a therapeutic protein consisting of the sequence provided in SEQ ID NO: 26 (anakinra); and a platelet-derived growth factor (PDGF) or another growth factor, in a therapeutically effective amount.
2 . The topical composition of claim 1 , wherein the composition is a gel, ointment, paste, lotion, powder, spray, or cream.
3 . The topical composition of claim 1 , further comprising a thickening agent.
4 . The topical composition of claim 3 , wherein the thickening agent is carboxymethylcellulose sodium.
5 . The topical composition of claim 1 , further comprising a surfactant.
6 . The topical composition of claim 5 , wherein the surfactant is a co-polymer having the formula
wherein x is 2 to 130, y is 15 to 70, and z is 2 to 130.
7 . The topical composition of claim 1 , further comprising a buffer.
8 . The topical composition of claim 7 , wherein the buffer comprises Phosphate Buffered Saline (PBS).
9 . The topical composition of claim 1 , formulated as an additive to a wound dressing.
10 . The topical composition of claim 9 , wherein the wound dressing comprises an adhesive bandage.
11 . The topical composition of claim 1 , wherein the PDGF is Becaplermin (Regnarex™)
12 . The topical composition of claim 1 , which is formulated to promote healing of a chronic wound in a diabetic subject.
13 . The tropical composition of claim 1 , wherein the growth factor is a transforming growth factor (TGF).Join the waitlist — get patent alerts
Track US2022202701A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.